Prognostic significance of Epstein–Barr virus DNA in NK/T-cell lymphoma: a meta-analysis

Qian Fei*
Xiao-Kang Tian*
Jing Wu
Hong-Ming Zhu
Yan Wang
Fan-Yu Peng
Wen-Jun Zhang
Li Yin
Xia He

Department of Radiation Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, People’s Republic of China

*These authors contributed equally to this work

Abstract: Extranodal NK/T-cell lymphoma is closely associated with Epstein–Barr virus (EBV) infection. However, the prognostic value of EBV-DNA in extranodal NK/T-cell lymphoma remains unclear. Thus, we conducted a meta-analysis to estimate its prognostic significance. PubMed, EMBASE, and Web of Science were used to search for studies conducted until June 12, 2017. The pooled hazard ratio (HR) and its 95% confidence interval (CI) were calculated to evaluate the prognostic value of pretreatment EBV-DNA on the overall survival of extranodal NK/T-cell lymphoma. Seven eligible studies on 356 patients with extranodal NK/T-cell lymphoma were pooled for this meta-analysis. Results suggested that the pretreatment EBV-DNA positivity was significantly correlated with the overall survival of extranodal NK/T-cell lymphoma (pooled HR = 3.78, 95% CI: 1.52–9.40, p = 0.004; heterogeneity test: I² = 52%, p = 0.05). Subgroup analyses stratified by sample type, survival analysis mode, and HR origin showed that patients with positive pretreatment EBV-DNA had poorer prognosis than those with negative pretreatment EBV-DNA. Moreover, the cut-off value (HR = 1.66; 95% CI: 0.73–3.73; p = 0.22) might account for the heterogeneity. No significant publication bias was observed. Pretreatment EBV-DNA positivity can predict poor prognosis for patients with extranodal NK/T-cell lymphoma. Future large-scale studies based on prognostic significance of EBV-DNA for patients with extranodal NK/T-cell lymphoma are necessary.

Keywords: extranodal natural killer/T-cell lymphoma, Epstein–Barr virus, prognosis, meta-analysis

Introduction

Extranodal natural killer/T-cell lymphoma (NK/TCL) is an Epstein–Barr virus (EBV)-associated and highly aggressive non-Hodgkin lymphoma with poor prognosis in advanced patients.1 NK/TCL is infrequent in Western countries but is the most prevalent subtype of peripheral T-cell lymphoma in China, and accounts for 47%–56% of peripheral T-cell lymphoma and 10%–15% of non-Hodgkin lymphoma.2,4 Concurrent chemoradiotherapy followed by non-anthracycline-based chemotherapy significantly improves the survival in NKTL.5–7 However, the survival outcome of NKTL remains poor because of relapse or treatment-related mortality. Therefore, good indicators for overall survival (OS) in NKTL should be identified. EBV is a ubiquitous γ-herpes virus that activates infected lymphocyte proliferation through the expression of growth-promoting latency genes and membrane proteins.8 The expression of EBV latent genes combined with other cofactors leads to virus-associated tumors such as NKTL.8 EBV-DNA can be detected by polymerase chain reaction (PCR) methods and has been used as a surrogate marker for evaluating tumor load in several EBV-associated malignancies.8–10 Recently, the results of some studies showed that pretreatment EBV-DNA levels are correlated with poorer prognosis in NKTL.11–15

Correspondence: Xia He; Li Yin
Department of Radiation Oncology, Jiangsu Cancer Hospital, 42 Baiziting, Nanjing, Jiangsu 210009, People’s Republic of China
Tel: +86 136 0145 8518; +86 139 1390 9043
Email: hexiabm@163.com; yinli_2012@126.com

OncoTargets and Therapy 2018:11 997–1004

© 2018 Fei et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial use only. Null commercial use of this work is permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
However, some showed that pretreatment EBV-DNA levels cannot be used as a prognostic factor for NKTCL. The prognostic value of pretreatment EBV-DNA levels remains controversial. Therefore, we conducted a meta-analysis to more precisely evaluate the association between EBV-DNA and the survival outcome of NKTCL.

Methods

This meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses.2,8

Search strategy

Three electronic databases (ie, PubMed, EMBASE, and Web of Science) were searched to examine the studies (published before June 12, 2017) that explored the prognostic value of EBV-DNA on the survival of NKTCL without geographic or language restrictions. Medical Subject Headings words that were used as keywords included the following: “Epstein-Barr virus,” “Extranodal NK-T-Cell Lymphoma,” and “prognosis.” Detailed search strategies that were used in the three electronic databases are described in Table S1. Meanwhile, we carefully screened the references of each retrieved relevant article to find other studies that satisfied the eligibility criteria. Disagreements were settled through discussions within our team.

Selection and exclusion criteria

The eligibility criteria of literature were as follows: 1) patients with confirmed NKTCL diagnosis according to the World Health Organization classification for lymphomas; 2) the study evaluated the relationship between EBV-DNA and patient OS; 3) the study reported a hazard ratio (HR) and 95% confidence interval (CI) or sufficient data to calculate the HR and 95% CI according to methods provided by Parmar et al;20,21 4) literature was published in full text. The exclusion criterion was when studies were published as reviews, comments, or conference abstracts.

Data extraction

Two investigators independently extracted useful data, using a predesigned table, from eligible studies. The following were included in the extracted information: first author’s full name, publication year, nationality and ethnicity of study population, number of patients with positive pretreatment EBV-DNA and negative pretreatment EBV-DNA, tumor stage, treatment, specimen, method of detection, cut-off value, HR, 95% CI, and whether multivariate analysis was performed. Disagreements were resolved through group discussion.

Quality assessment

Two researchers evaluated the study quality according to the Newcastle–Ottawa Scale (Table S2).22 The following were included in the main categories used to assess each study: selection, comparability, and outcome. The Newcastle–Ottawa Scale scores ranged from 0 to 9, and scores ≥6 indicated high quality. Disagreements were settled through group discussion.

Statistical analysis

HR was the most appropriate effect measure to analyze time-to-event data. The prognostic value of EBV-DNA on OS was estimated by HR and the corresponding 95% CI. The most accurate method for determining HR and 95% CI was to directly retrieve them from the reported results. However, if the study did not report the HR and 95% CI, these can be calculated by extracting survival rates from OS curves.23 Moreover, we defined HR >1 as a poor prognosis for the patients with positive EBV-DNA. We used Revman5.3 Software (Review Manager 5 is the software used for preparing and maintaining Cochrane Reviews) to perform the meta-analysis, and the heterogeneity of studies was assessed using Cochrane’s Q test ($\chi^2$ test) and $I^2$ metric.24 $I^2$<25% was defined as low heterogeneity, $I^2$=25%-50% was defined as moderate heterogeneity, and $I^2$>50% was defined as significant heterogeneity.25 A fixed-effect model was used in the meta-analysis when no significant heterogeneity ($I^2$<50% or $p$$\geq$0.1) was detected between studies. Otherwise, the random-effect model was selected.

Publication bias was evaluated by Begg’s test. Kaplan–Meier curves were analyzed using Engauge Digitizer version 4.1. Statistical analysis was performed using Stata software (version 12.0; StataCorp., College Station, TX, USA). All $p$-values were two-sided. $p$-values <0.05 were considered as statistically significant.

Results

Characteristics of studies

A total of 458 articles were selected through searching the databases, and 216 overlapping studies were excluded. After screening the titles and abstracts, 23 studies that might satisfy the inclusion criteria were assessed by reviewing the full texts. As a result, seven eligible studies on 356 patients with NKTCL were included for the meta-analysis (Figure 1). The main characteristics and data of included studies are shown...
in Table 1. All of the patients included in our analysis were Asian, and real-time PCR was the method used for EBV-DNA detection in all eligible studies. The cut-off values were different within the studies, because the cut-off definition of EBV-DNA has not been standardized. Four studies reported HR with 95% CI, and the remaining studies calculated HR and 95% CI from their Kaplan–Meier survival curves. Four studies used whole blood, and the other three studies used plasma due to the lack of consensus on the best blood sample type for EBV-DNA detection.

Prognostic value of pretreatment EBV-DNA in NKTCL

As shown in Figure 2, the pretreatment EBV-DNA was significantly correlated with the OS of NKTCL patients (HR=3.78, 95% CI: 1.52–9.40, Z=2.85, p=0.004, random-effect), and pretreatment EBV-DNA positivity could be used as a predictor for adverse outcomes in NKTCL. The results of Q test and I² test showed a significant heterogeneity across studies (p=0.05, I²=52%). Therefore, subgroup analyses stratified by sample type, cut-off value, survival analysis mode, and HR origin were further conducted to detect the heterogeneity among eligible studies (Table 2). The results of subgroup analyses, which implied that patients with positive pretreatment EBV-DNA had poorer OS than those with negative pretreatment EBV-DNA, were as follows: whole blood subgroup (HR=2.15; 95% CI: 1.17–3.94; p=0.01),

Table 1: Main characteristics and data of included studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Country</th>
<th>Dominant Pretreatment ethnicity</th>
<th>Pretreatment cut-off (copies/mL)</th>
<th>Tumor stage</th>
<th>Treatment</th>
<th>Multivariate analysis</th>
<th>Source of HR</th>
<th>Outcome</th>
<th>Quality score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kim et al, 2009</td>
<td>South Korea</td>
<td>Asian</td>
<td>63.61</td>
<td>I, II/III, IV</td>
<td>WB</td>
<td>rt-PCR</td>
<td>NA</td>
<td>NO</td>
<td>OS</td>
</tr>
<tr>
<td>Wang et al, 2015</td>
<td>People's Republic of China</td>
<td>Asian</td>
<td>0</td>
<td>I, II/III, IV</td>
<td>Plasma</td>
<td>rt-PCR</td>
<td>31/14</td>
<td>Yes</td>
<td>OS, PFS</td>
</tr>
<tr>
<td>Ye et al, 2012</td>
<td>Japan</td>
<td>Asian</td>
<td>0</td>
<td>I, II/III, IV</td>
<td>WB</td>
<td>r-PCR</td>
<td>10/56</td>
<td>No</td>
<td>RT/2, CT/6, CRT/16</td>
</tr>
<tr>
<td>Suzuki et al, 2011</td>
<td>Japan</td>
<td>Asian</td>
<td>105</td>
<td>I, II/III, IV</td>
<td>WB</td>
<td>rt-PCR</td>
<td>NA</td>
<td>Yes</td>
<td>OS</td>
</tr>
<tr>
<td>Chen et al, 2017</td>
<td>People's Republic of China</td>
<td>Asian</td>
<td>5,000</td>
<td>I, II/III, IV</td>
<td>Plasma</td>
<td>rt-PCR</td>
<td>NA</td>
<td>Yes</td>
<td>OS</td>
</tr>
<tr>
<td>Wang et al, 2012</td>
<td>People's Republic of China</td>
<td>Asian</td>
<td>0</td>
<td>I, II/III, IV</td>
<td>WB</td>
<td>rt-PCR</td>
<td>69/0</td>
<td>No</td>
<td>RT/36, RT+CT/33</td>
</tr>
<tr>
<td>Kim et al, 2016</td>
<td>South Korea</td>
<td>Asian</td>
<td>0</td>
<td>I, II/III, IV</td>
<td>WB</td>
<td>rt-PCR</td>
<td>40/27</td>
<td>Yes</td>
<td>OS</td>
</tr>
</tbody>
</table>

Abbreviations: EBV, Epstein–Barr virus; HR, hazard ratio; WB, whole blood; rt-PCR, real-time polymerase chain reaction; NA, not available; OS, overall survival; SC, survival curve; CT, chemotherapy; RT, radiotherapy; CRT, concurrent chemoradiotherapy; PFS, progression free survival.
plasma subgroup (HR = 5.31; 95% CI: 1.42–19.88; p = 0.01), cut-off value >0 copies/mL subgroup (HR = 3.60; 95% CI: 1.70, 7.62; p = 0.0008), multivatiate analysis subgroup (HR = 2.24; 95% CI: 1.05–4.79; p = 0.04), non-multivariate analysis subgroup (HR = 2.86; 95% CI: 1.28–6.38; p = 0.001), HR reported subgroup (HR = 2.65; 95% CI: 1.29–5.48; p = 0.008), and HR calculated from survival curve subgroup (HR = 2.34; 95% CI: 1.00–5.47; p = 0.05). Moreover, the results of subgroup analyses indicated that the cut-off value (HR = 1.66; 95% CI: 0.73–3.73; p = 0.22) might account for the heterogeneity.

**Publication bias and sensitivity analysis**

We used Stata12.0 software to conduct Begg’s text to estimate the publication bias. As shown in Figure 3, no evidence of publication bias was observed according to Begg’s tests (p = 0.072).

Moreover, we performed sensitivity analysis to assess the influence of each individual study on the combined effect size. Results suggested that no individual study significantly influenced our final outcome (Figure 4), which demonstrated that this meta-analysis is relatively stable and statistically reliable.

**Discussion**

Meta-analysis is considered as an important tool to objectively evaluate evidence. At present, no systematic review about the prognostic value of EBV-DNA for NKTCL is available. For the first time, this meta-analysis overcame the limitation of sample size, suggesting that the patients with positive pretreatment EBV-DNA had significantly inferior outcome to those with negative pretreatment EBV-DNA.

There are many NKTCL-associated prognostic factors that have been reported so far, such as age, LDH level, Ann Arbor stage, etc. However, in Wang et al’s study,14 most risk factors of previous prognostic models (Korean Prognostic Index [KPI], International Prognostic Index [IPI]) were found to be unrelated with survival outcomes, indicating the poor survival

---

**Table 2** The prognostic impact of pretreatment EBV-DNA in NKTCL according to subgroup analysis

<table>
<thead>
<tr>
<th>Subgroup analysis</th>
<th>Number of studies</th>
<th>HR (95% CI)</th>
<th>Z</th>
<th>p-value</th>
<th>Model</th>
<th>Test of heterogeneity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall</td>
<td>7</td>
<td>3.78 (1.52–9.40)</td>
<td>2.85</td>
<td>0.004</td>
<td>Random</td>
<td>12.39</td>
</tr>
<tr>
<td>Sample</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WB</td>
<td>4</td>
<td>2.15 (1.17–3.94)</td>
<td>2.48</td>
<td>0.01</td>
<td>Fixed</td>
<td>10.21</td>
</tr>
<tr>
<td>Plasma</td>
<td>3</td>
<td>5.31 (1.42–19.88)</td>
<td>2.48</td>
<td>0.01</td>
<td>Fixed</td>
<td>0.70</td>
</tr>
<tr>
<td>Cut-off (copies/mL)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>3</td>
<td>1.66 (0.73–3.73)</td>
<td>1.22</td>
<td>0.22</td>
<td>Fixed</td>
<td>3.88</td>
</tr>
<tr>
<td>&gt;0</td>
<td>4</td>
<td>3.60 (1.70–7.62)</td>
<td>3.35</td>
<td>0.0008</td>
<td>Fixed</td>
<td>6.62</td>
</tr>
<tr>
<td>Multivariate analysis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>4</td>
<td>2.24 (1.05–4.79)</td>
<td>2.09</td>
<td>0.04</td>
<td>Fixed</td>
<td>10.28</td>
</tr>
<tr>
<td>No</td>
<td>3</td>
<td>2.86 (1.28–6.38)</td>
<td>2.57</td>
<td>0.001</td>
<td>Fixed</td>
<td>1.93</td>
</tr>
<tr>
<td>Source of HR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SC</td>
<td>3</td>
<td>2.34 (1.00–5.47)</td>
<td>1.96</td>
<td>0.05</td>
<td>Fixed</td>
<td>0.24</td>
</tr>
<tr>
<td>Reported</td>
<td>4</td>
<td>2.65 (1.29–5.48)</td>
<td>2.64</td>
<td>0.008</td>
<td>Fixed</td>
<td>12.10</td>
</tr>
</tbody>
</table>

**Abbreviations:** EBV, Epstein–Barr virus; NKTCL, extranodal natural killer/T-cell lymphoma; HR, hazard ratio; CI, confidence interval; WB, whole blood; SC, survival curve.
outcomes brought by age, LDH level, Ann Arbor stage, etc. might be overcome by new treatment. EBV-DNA is derived from necrotic or apoptotic tumor cells, and thus it is strongly associated with prognosis of NKTCL patients. Previous studies found that pretreatment EBV-DNA levels can reflect the tumor burden. Therefore, using EBV-DNA as a prognostic biomarker for NKTCL is reasonable and significant.

In 2009, Kim et al reported the prognostic value of pretreatment EBV-DNA in the whole blood for patients with NKTCL. In Ito et al’s study, besides finding the significant association between pretreatment EBV-DNA and OS in NKTCL, consistent with the abovementioned result, they reported that pretreatment EBV-DNA was frequently detected in whole blood samples. However, in a 2016 study, researchers found that comparing with peripheral blood mononuclear cells, plasma appears to be a better specimen source when evaluating for EBV+ disease response to therapy. However, Kim et al found that the proportion of patients with positive pretreatment EBV-DNA was not related to the type of sample tested (ie, plasma vs whole blood; \( p=0.51 \)). Moreover, EBV-DNA was initially regarded as an independent risk factor in a prognostic model, which was established for patients with NKTCL in Kim et al’s study. The results of our subgroup analysis stratified by sample type were consistent with these previous studies. However, Tse and Kwong thought that whole blood was not the suitable material: first, because the quantitative mean of EBV-DNA level varies according to the leukocyte count; and second, circulating long-lived memory B cells infected with EBV may interfere with the results of EBV-DNA testing. The study by Wang et al suggested that pretreatment EBV-DNA level independently had no impact on prognosis for the early stage NKTCL patients, but the posttreatment plasma EBV-DNA level could predict early relapse and poor prognosis. Similarly, the multivariate analysis by Kwong et al showed
that pretreatment EBV-DNA levels, although accurate as a tumor load biomarker, did not independently affect survival; the changes in EBV-DNA after SMILE (dexamethasone, methotrexate, ifosfamide, petylase, etoposide) treatment might be better to indicate tumor chemosensitivity and thus influence survival. The inconsistent prognostic value of pretreatment EBV-DNA might be related to the different chemotherapy regimens in different studies. In the studies by Wang et al\(^1\) and Kwong et al,\(^2\) all patients were treated with asparaginase-based therapy, whereas some patients in our meta-analysis were given conventional chemotherapy, such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) and CHOP-like regimens. Previous studies showed that patients with NKTCL have poor responses to anthracycline-containing chemotherapy because of the multidrug-resistant P-glycoprotein expressed by natural killer cells.\(^3\) Therefore, whether patients received anthracycline-containing chemotherapy was considered as a factor that could confound the assessment of prognostic value of pretreatment EBV-DNA.

Some limitations exist in our analysis. First, a significant heterogeneity was observed within the studies. Subgroup analyses were further performed. Results revealed that cut-off values might contribute to the heterogeneity. Second, all patients in this meta-analysis were Asian. However, ethnic bias is likely to be small because the universal association of NKTCL with EBV across all ethnic groups suggests a common pathogenesis.\(^3\) Third, some HRs and 95% CIs were not directly extracted from the studies but were calculated according to Kaplan–Meier survival curves. Hence, the errors were inevitable. However, we strictly followed the methods provided by Tierney et al to extract survival rates from OS curves. Extraction for each OS curve was repeated three times to minimize errors to a great extent. Fourth, not all of the patients in our analysis received asparaginase-based chemotherapy. Different types of chemotherapy regimens lead to different survival outcomes, which may influence our final results. Fifth, at present, no consensus exists for the most appropriate cut-off value to be used for the measurement of EBV-DNA. The subgroup analysis results of this study indicated that the cut-off value may affect the final results of analysis. Therefore, the results of the analysis should be re-evaluated if the issues related to the cut-off value, to be used for the EBV-DNA testing, are resolved in future studies. Moreover, considering the rarity of this disease, the sample size of eligible studies was not large enough, which might be one of the reasons for the \(p\)-value = 0.05 in the results of the Q test and \(I^2\) text. Therefore, more large-scale studies should be performed to further validate the results.

## Conclusion

The results of this meta-analysis suggested that pretreatment EBV-DNA positivity had an adverse effect on the survival outcome of NKTCL, despite these limitations mentioned herein before. Clinicians can formulate specific treatment regimens for NKTCL patients based on pretreatment EBV-DNA levels. In addition, further large-scale studies regarding prognostic value of pretreatment EBV-DNA in NKTCL should be conducted to validate our findings in the era of asparaginase-based chemotherapy.

## Acknowledgment

This research was supported by grants from the Six Major Talent Peak Project of Jiangsu Province (class B, no WS-047).

## Author contribution

QF, XKT, and LY designed the systematic review; WJZ, YW, FYP, HMZ, and JW were involved in the literature search and study selection; WJZ, YW, FYP, HMZ, and JW extracted the data from eligible studies; QF and XKT conducted the analysis; QF, XKT, LY, and XH were involved in the interpretation of the results. QF, XKT, LY, and XH were responsible for the writing and critical revisions of the manuscript. All authors read and approved the final manuscript. All authors contributed toward data analysis, drafting and revising the paper and agree to be accountable for all aspects of the work.

## Disclosure

The authors report no conflicts of interest in this work.

## References


Supplementary materials

Table S1 Search strategies for three electronic databases

<table>
<thead>
<tr>
<th>Electronic database</th>
<th>Search strategy</th>
</tr>
</thead>
<tbody>
<tr>
<td>PubMed</td>
<td>(Extranodal NK-T-Cell Lymphoma[Title/Abstract]) AND (prognosis[Title/Abstract] OR (EBV DNA[Title/Abstract]))</td>
</tr>
<tr>
<td>EMBASE</td>
<td>‘nk t cell lymphoma’:ab,ti OR ‘extranodal nk/t cell lymphoma’:ab,ti AND ‘prognosis’:ab,ti AND (‘epstein barr virus’:ab,ti OR ‘ebv’:ab,ti) AND [embase]/lim</td>
</tr>
<tr>
<td>Web of Science</td>
<td>(extranodal nk/t cell lymphoma) AND (epstein barr virus) AND prognosis</td>
</tr>
</tbody>
</table>

Table S2 Newcastle–Ottawa quality assessment scale

Assessment of quality of a cohort study – Newcastle–Ottawa Scale

Comparability (tick one or both boxes, as appropriate)
1. Comparability of cohorts on the basis of the design or analysis
   a) Study controls for age, sex, marital status
   b) Study controls for any additional factors (eg, socioeconomic status, education)

Outcome (tick one box in each section)
1. Assessment of outcome
   a) Independent blind assessment
   b) Record linkage
   c) Self-report
   d) Other/no description

2. Was follow-up long enough for outcomes to occur
   a) Yes, if median duration of follow-up ≥6 months
   b) No, if median duration of follow-up <6 months

3. Adequacy of follow-up of cohorts
   a) Complete follow-up: all subjects accounted for
   b) Subjects lost to follow-up unlikely to introduce bias: number lost ≤20%, or description of those lost suggesting no different from those followed
   c) Follow-up rate <80% (select an adequate %) and no description of those lost
   d) No statement

(Continued)

Assessment of quality of a cohort study – Newcastle–Ottawa Scale (Continued)

Comparability (tick one or both boxes, as appropriate)
1. Comparability of cohorts on the basis of the design or analysis
   a) Study controls for age, sex, marital status
   b) Study controls for any additional factors (eg, socioeconomic status, education)

Outcome (tick one box in each section)
1. Assessment of outcome
   a) Independent blind assessment
   b) Record linkage
   c) Self-report
   d) Other/no description

2. Was follow-up long enough for outcomes to occur
   a) Yes, if median duration of follow-up ≥6 months
   b) No, if median duration of follow-up <6 months

3. Adequacy of follow-up of cohorts
   a) Complete follow-up: all subjects accounted for
   b) Subjects lost to follow-up unlikely to introduce bias: number lost ≤20%, or description of those lost suggesting no different from those followed
   c) Follow-up rate <80% (select an adequate %) and no description of those lost
   d) No statement

(Continued)